Form 144 - Report of proposed sale of securities
SEC Accession No. 0002086827-26-000006
Filing Date
2026-02-04
Accepted
2026-02-04 18:39:54
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 4832
  Complete submission text file 0002086827-26-000006.txt   6336
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Subject) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-39536 | Film No.: 26599758
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, SUITE 1430 DALLAS TX 75247
Business Address
Haque-Ahmed Rumana (Reporting) CIK: 0002086827 (see all company filings)

Type: 144